NO953033L - Stabile baktericid/permeabilitetsökende proteinprodukter og farmasöytiske preparater inneholdende disse - Google Patents
Stabile baktericid/permeabilitetsökende proteinprodukter og farmasöytiske preparater inneholdende disseInfo
- Publication number
- NO953033L NO953033L NO953033A NO953033A NO953033L NO 953033 L NO953033 L NO 953033L NO 953033 A NO953033 A NO 953033A NO 953033 A NO953033 A NO 953033A NO 953033 L NO953033 L NO 953033L
- Authority
- NO
- Norway
- Prior art keywords
- residue
- protein products
- pharmaceutical preparations
- preparations containing
- increasing protein
- Prior art date
Links
- 230000000844 anti-bacterial effect Effects 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 239000003899 bactericide agent Substances 0.000 title 1
- 230000035699 permeability Effects 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 1
- 208000027096 gram-negative bacterial infections Diseases 0.000 abstract 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/013,801 US5420019A (en) | 1993-02-02 | 1993-02-02 | Stable bactericidal/permeability-increasing protein muteins |
PCT/US1994/001235 WO1994018323A1 (en) | 1993-02-02 | 1994-02-02 | Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same |
Publications (3)
Publication Number | Publication Date |
---|---|
NO953033D0 NO953033D0 (no) | 1995-08-01 |
NO953033L true NO953033L (no) | 1995-10-02 |
NO315705B1 NO315705B1 (no) | 2003-10-13 |
Family
ID=21761817
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19953033A NO315705B1 (no) | 1993-02-02 | 1995-08-01 | Baktericid/permeabilitetsökende protein eller et fragment derav, DNA som koder for dette, autonomt replikerende DNA-vektor, vertscelle,fremgangsmåte for fremstilling av dette, hybrid fusjonsprotein, farmasöytiskpreparat, polypeptid for medisin |
NO20023224A NO319156B1 (no) | 1993-02-02 | 2002-07-03 | DNA som koder for et biologisk aktivt fragment av baktericid/permeabilitetsokende protein, fremgangsmate for fremstilling av dette, samt farmasoytisk preparat inneholdende dette og isolert, biologisk aktivt fragment av baktericid/permeabilitetsokende protein. |
NO20050998A NO20050998D0 (no) | 1993-02-02 | 2005-02-24 | DNA som koder for et biologisk aktivt fragment av baktericid/premeabilitetsokende protein fremgangsmate for fremstilling av dette, samt farmasoytisk preparat inneholdende dette |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20023224A NO319156B1 (no) | 1993-02-02 | 2002-07-03 | DNA som koder for et biologisk aktivt fragment av baktericid/permeabilitetsokende protein, fremgangsmate for fremstilling av dette, samt farmasoytisk preparat inneholdende dette og isolert, biologisk aktivt fragment av baktericid/permeabilitetsokende protein. |
NO20050998A NO20050998D0 (no) | 1993-02-02 | 2005-02-24 | DNA som koder for et biologisk aktivt fragment av baktericid/premeabilitetsokende protein fremgangsmate for fremstilling av dette, samt farmasoytisk preparat inneholdende dette |
Country Status (19)
Country | Link |
---|---|
US (6) | US5420019A (no) |
EP (3) | EP1013760B1 (no) |
JP (4) | JP4139867B2 (no) |
KR (1) | KR100361997B1 (no) |
CN (1) | CN1142996C (no) |
AT (3) | ATE363535T1 (no) |
AU (1) | AU693089B2 (no) |
CA (1) | CA2155004C (no) |
DE (3) | DE69426019T2 (no) |
DK (2) | DK0689592T3 (no) |
ES (2) | ES2150983T3 (no) |
FI (2) | FI112367B (no) |
GR (1) | GR3034492T3 (no) |
HK (1) | HK1014548A1 (no) |
NO (3) | NO315705B1 (no) |
NZ (1) | NZ262284A (no) |
PT (2) | PT689592E (no) |
WO (1) | WO1994018323A1 (no) |
ZA (1) | ZA94703B (no) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5198541A (en) * | 1987-08-11 | 1993-03-30 | New York University | Dna encoding bactericidal/permeability-increasing proteins |
US6265187B1 (en) * | 1989-02-14 | 2001-07-24 | Incyte Pharmaceuticals, Inc. | Recombinant endotoxin-neutralizing proteins |
US5840836A (en) * | 1989-02-17 | 1998-11-24 | Bayer Corporation | Pancreatic islet cell antigens obtained by molecular cloning |
US6811989B1 (en) * | 1989-02-17 | 2004-11-02 | Bayer Corporation | Pancreatic islet cell antigens obtained by molecular cloning |
US6274348B1 (en) | 1992-05-19 | 2001-08-14 | Xoma Corporation | Methods for the preparation of positively charged proteins |
AU4382193A (en) * | 1992-05-19 | 1993-12-13 | Xoma Corporation | BPI-immunoglobulin fusion proteins |
US5420019A (en) * | 1993-02-02 | 1995-05-30 | Xoma Corporation | Stable bactericidal/permeability-increasing protein muteins |
US6214789B1 (en) | 1993-03-12 | 2001-04-10 | Xoma Corporation | Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products |
US5652332A (en) * | 1993-03-12 | 1997-07-29 | Xoma | Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof |
WO1994020128A1 (en) * | 1993-03-12 | 1994-09-15 | Xoma Corporation | Therapeutic uses of bactericidal/permeability increasing protein products |
AU7175694A (en) | 1993-06-17 | 1995-01-17 | Xoma Corporation | Lipopolysaccharide binding protein derivatives |
WO1995002414A1 (en) * | 1993-07-14 | 1995-01-26 | Xoma Corporation | Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products |
US5770561A (en) * | 1993-07-14 | 1998-06-23 | Xoma Corporation | Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products |
US6759203B1 (en) | 1993-09-22 | 2004-07-06 | Xoma Corporation | Method for quantifying BPI in body fluids |
PT759774E (pt) * | 1993-09-22 | 2002-11-29 | Xoma Technology Ltd | Metodo para o tratamento de infeccoes bacterianas gram-negativas por administracao de um produto de proteina bactericida indutora da permeabilidade (bip) e de um antibiotico |
CN1133634A (zh) * | 1993-09-22 | 1996-10-16 | 爱克斯欧玛公司 | 定量体液中的bpi的方法 |
AU703211B2 (en) * | 1994-01-14 | 1999-03-18 | Xoma Corporation | Anti-fungal methods and materials |
EP0754050B1 (en) * | 1994-01-14 | 2002-06-26 | XOMA Technology Ltd. | Anti gram positive bacterial methods and materials |
US5447913A (en) | 1994-03-11 | 1995-09-05 | Xoma Corporation | Therapeutic uses of bactericidal/permeability-increasing protein dimer products |
US5786324A (en) * | 1994-03-24 | 1998-07-28 | Regents Of The University Of Minnesota | Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use |
US5830860A (en) * | 1994-03-24 | 1998-11-03 | Regents Of The University Of Minnesota | Peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use |
US5578568A (en) * | 1994-04-22 | 1996-11-26 | Xoma Corporation | Method of treating conditions associated with intestinal ischemia/reperfusion |
US6271203B1 (en) | 1994-07-07 | 2001-08-07 | Xoma Corporation | Anti-protozoan methods and materials |
US5646114A (en) * | 1994-07-11 | 1997-07-08 | Xoma Corporation | Anti-protozoan methods |
WO1996014428A1 (en) * | 1994-11-08 | 1996-05-17 | Novagen, Inc. | Method for in vitro protein synthesis |
US5494896A (en) * | 1995-03-31 | 1996-02-27 | Xoma Corporation | Method of treating conditions associated with burn injuries |
JP2001520631A (ja) * | 1995-07-20 | 2001-10-30 | ゾーマ コーポレイション | 抗真菌性ペプチド |
EP0861088A1 (en) * | 1995-11-14 | 1998-09-02 | Xoma Corporation | Bactericidal permeability increasing protein (bpi) for treating conditions associated with corneal injury |
US5686414A (en) * | 1995-11-14 | 1997-11-11 | Xoma Corporation | Methods of treating conditions associated with corneal transplantation |
US5856159A (en) * | 1996-03-27 | 1999-01-05 | Cytel Corporation | Production of galactosyltransferase |
NZ332720A (en) | 1996-05-10 | 2000-07-28 | Xoma Corp | Therapeutic uses of bactericidal/permeability increasing (BPI) protein to treat human meningococcemia |
US5741779A (en) * | 1996-05-10 | 1998-04-21 | Xoma Corporation | Antithrombotic materials and methods |
CA2255539C (en) * | 1996-05-23 | 2005-09-27 | Xoma Corporation | Therapeutic uses of bpi protein products in humans with hemorrhage due to trauma |
US6486125B1 (en) | 1996-05-24 | 2002-11-26 | Regents Of The University Of Minnesota | Synthesis of soluble β-sheet forming peptides |
US5888973A (en) | 1996-08-09 | 1999-03-30 | Xoma Corporation | Anti-chlamydial uses of BPI protein products |
US6482796B2 (en) * | 1996-11-01 | 2002-11-19 | Xoma Corporation | Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients |
CN1062564C (zh) * | 1996-12-20 | 2001-02-28 | 周红 | 猪血中提纯杀菌性/通透性增加蛋白的方法 |
ATE291617T1 (de) * | 1997-01-24 | 2005-04-15 | Avi Biopharm Inc | Verfahren und konjugat zur behandlung von helicobacter pylori-infektionen |
US6093573A (en) * | 1997-06-20 | 2000-07-25 | Xoma | Three-dimensional structure of bactericidal/permeability-increasing protein (BPI) |
FR2767323B1 (fr) * | 1997-08-12 | 2001-01-05 | Synt Em | Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives |
US6013631A (en) * | 1998-06-19 | 2000-01-11 | Xoma Corporation | Bactericidal/permeability-increasing protein (BPI) deletion analogs |
US6156514A (en) * | 1998-12-03 | 2000-12-05 | Sunol Molecular Corporation | Methods for making recombinant cells |
US6242219B1 (en) | 1999-03-18 | 2001-06-05 | Xoma (Us) Llc | Methods for recombinant peptide production |
US6153584A (en) * | 1999-04-01 | 2000-11-28 | Levy; Ofer | Therapeutic uses of BPI protein products in BPI-deficient humans |
US7041644B2 (en) * | 1999-04-01 | 2006-05-09 | Xoma Technology | Therapeutic uses of BPI protein products in BPI-deficient humans |
WO2001025254A2 (en) | 1999-10-04 | 2001-04-12 | University Of Maryland Biotechnology Institute | Novel adjuvant comprising a lipopolysaccharide antagonist |
AU2002241589B2 (en) * | 2000-12-01 | 2007-07-19 | Xoma Technology Ltd. | Modulation of pericyte proliferation using BPI protein products or BPI inhibitors |
US20030049616A1 (en) * | 2001-01-08 | 2003-03-13 | Sydney Brenner | Enzymatic synthesis of oligonucleotide tags |
WO2002070667A2 (en) * | 2001-03-05 | 2002-09-12 | Transtech Pharma, Inc. | High level insect expression of rage proteins |
EP1572719A4 (en) | 2002-02-20 | 2007-11-14 | Univ Minnesota | PARTIAL PEPTIDE MIMETICS AND METHOD |
JP2005521401A (ja) * | 2002-03-27 | 2005-07-21 | イミュネックス・コーポレーション | ポリペプチド産生を増加させる方法 |
DE60335794D1 (de) | 2002-03-29 | 2011-03-03 | Xoma Technology Ltd | Multigene vectoren und methoden für eine erhöhte expression von rekombinanten polypeptiden |
US7906722B2 (en) * | 2005-04-19 | 2011-03-15 | Palo Alto Research Center Incorporated | Concentrating solar collector with solid optical element |
EP1741440A1 (en) | 2005-07-08 | 2007-01-10 | Mellitus S.L. | Use of BPI protein for the treatment of disorders of the metabolism and cardiovascular disorders |
EP2592148B1 (en) | 2007-10-12 | 2018-09-12 | F. Hoffmann-La Roche AG | Protein expression from multiple nucleic acids |
US9770483B2 (en) | 2011-04-05 | 2017-09-26 | Dana-Farber Cancer Institute, Inc. | BPI and its congeners as radiation mitigators and radiation protectors |
GB201319620D0 (en) | 2013-11-06 | 2013-12-18 | Norwegian University Of Science And Technology | Immunosuppressive agents and their use in therapy |
GB201319621D0 (en) | 2013-11-06 | 2013-12-18 | Norwegian University Of Science And Technology | Antimicrobial agents and their use in therapy |
NZ756132A (en) | 2017-03-10 | 2022-02-25 | Hoffmann La Roche | Method for producing multispecific antibodies |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4588585A (en) * | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
US4853332A (en) * | 1982-10-19 | 1989-08-01 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins |
US4518584A (en) * | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
US4816566A (en) * | 1983-06-01 | 1989-03-28 | Hoffmann-La Roche, Inc. | Polypeptides having interferon activity |
US4879226A (en) * | 1984-04-06 | 1989-11-07 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel human physiologically active polypeptide |
US4677063A (en) * | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
US4677064A (en) * | 1984-11-09 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
US4959314A (en) * | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
US5206344A (en) * | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US5198541A (en) * | 1987-08-11 | 1993-03-30 | New York University | Dna encoding bactericidal/permeability-increasing proteins |
US5576292A (en) * | 1987-08-11 | 1996-11-19 | New York University | Biologically active bactericidal/permeability-increasing protein fragments |
EP0652230B1 (en) * | 1987-08-11 | 2005-12-14 | New York University | Biologically active bactericidal/permeability-increasing protein fragments |
US5308834A (en) * | 1989-02-14 | 1994-05-03 | Incyte Pharmaceuticals, Inc. | Treatment of endotoxin-associated shock and prevention thereof using a BPI protein |
US5234912A (en) * | 1989-02-14 | 1993-08-10 | Incyte Pharmaceuticals, Inc. | Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof |
US5089274A (en) * | 1989-02-14 | 1992-02-18 | Incyte Pharmaceuticals, Inc. | Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders |
US5770694A (en) * | 1990-08-13 | 1998-06-23 | Incyte Pharmaceuticals, Inc. | Genetically engineered BPI variant proteins |
US5334584A (en) * | 1989-02-14 | 1994-08-02 | Incyte Pharamaceuticals, Inc. | Recombinant, non-glycosylated bpi protein and uses thereof |
US5171739A (en) * | 1989-02-14 | 1992-12-15 | Incyte Pharmaceuticals, Inc. | Treatment of endotoxin-associated shock and preventation thereof using a BPI protein |
US5166322A (en) * | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
WO1992009621A1 (en) * | 1990-12-03 | 1992-06-11 | New York University | Biologically active bactericidal/permeability-increasing protein fragments |
EP0605653A4 (en) * | 1991-09-26 | 1995-03-15 | Incyte Pharma Inc | NEW LIPOSACCHARID BINDING PROTEIN (LBP). |
HUT65528A (en) * | 1991-10-31 | 1994-06-28 | Lee | Electronic identifying system enabling automatized remote response |
DK0642579T3 (da) * | 1992-05-19 | 1999-10-18 | Xoma Corp | Forbedrede fremgangsmåder til fremstilling af endotoxin-bindende proteiner |
AU4382193A (en) * | 1992-05-19 | 1993-12-13 | Xoma Corporation | BPI-immunoglobulin fusion proteins |
US5420019A (en) * | 1993-02-02 | 1995-05-30 | Xoma Corporation | Stable bactericidal/permeability-increasing protein muteins |
CN1163264C (zh) * | 1993-02-02 | 2004-08-25 | 爱克索马技术有限公司 | 改进的药物组合物 |
US5348942A (en) * | 1993-03-12 | 1994-09-20 | Xoma Corporation | Therapeutic uses of bactericidal/permeability increasing protein products |
EP0690872B1 (en) * | 1993-03-12 | 1998-08-05 | Xoma Corporation | Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof |
WO1994020129A1 (en) * | 1993-03-12 | 1994-09-15 | Xoma Corporation | Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products |
WO1994020128A1 (en) * | 1993-03-12 | 1994-09-15 | Xoma Corporation | Therapeutic uses of bactericidal/permeability increasing protein products |
EP0760849A1 (en) * | 1993-04-30 | 1997-03-12 | Incyte Pharmaceuticals, Inc. | Recombinant bpi-based and lbp-based proteins, nucleic acid molecules encoding same, methods of producing same, and uses thereof |
-
1993
- 1993-02-02 US US08/013,801 patent/US5420019A/en not_active Expired - Lifetime
-
1994
- 1994-02-02 JP JP51821094A patent/JP4139867B2/ja not_active Expired - Fee Related
- 1994-02-02 KR KR1019950703197A patent/KR100361997B1/ko not_active IP Right Cessation
- 1994-02-02 ZA ZA94703A patent/ZA94703B/xx unknown
- 1994-02-02 DK DK94908704T patent/DK0689592T3/da active
- 1994-02-02 AT AT03000252T patent/ATE363535T1/de not_active IP Right Cessation
- 1994-02-02 DE DE69426019T patent/DE69426019T2/de not_active Expired - Lifetime
- 1994-02-02 DE DE69434980T patent/DE69434980T2/de not_active Expired - Fee Related
- 1994-02-02 AT AT94908704T patent/ATE196650T1/de not_active IP Right Cessation
- 1994-02-02 DE DE69431995T patent/DE69431995T2/de not_active Expired - Fee Related
- 1994-02-02 EP EP00103901A patent/EP1013760B1/en not_active Expired - Lifetime
- 1994-02-02 ES ES94908704T patent/ES2150983T3/es not_active Expired - Lifetime
- 1994-02-02 AU AU61702/94A patent/AU693089B2/en not_active Ceased
- 1994-02-02 NZ NZ262284A patent/NZ262284A/en not_active IP Right Cessation
- 1994-02-02 EP EP03000252A patent/EP1310558B1/en not_active Expired - Lifetime
- 1994-02-02 ES ES03000252T patent/ES2288199T3/es not_active Expired - Lifetime
- 1994-02-02 DK DK03000252T patent/DK1310558T3/da active
- 1994-02-02 EP EP94908704A patent/EP0689592B1/en not_active Expired - Lifetime
- 1994-02-02 PT PT94908704T patent/PT689592E/pt unknown
- 1994-02-02 WO PCT/US1994/001235 patent/WO1994018323A1/en active IP Right Grant
- 1994-02-02 CA CA2155004A patent/CA2155004C/en not_active Expired - Fee Related
- 1994-02-02 AT AT00103901T patent/ATE230797T1/de not_active IP Right Cessation
- 1994-02-02 CN CNB941916723A patent/CN1142996C/zh not_active Expired - Fee Related
- 1994-02-02 PT PT03000252T patent/PT1310558E/pt unknown
-
1995
- 1995-04-28 US US08/430,417 patent/US5674834A/en not_active Expired - Lifetime
- 1995-06-06 US US08/466,822 patent/US5827816A/en not_active Expired - Lifetime
- 1995-08-01 NO NO19953033A patent/NO315705B1/no not_active IP Right Cessation
- 1995-08-01 FI FI953658A patent/FI112367B/fi active
-
1998
- 1998-12-28 HK HK98115811A patent/HK1014548A1/xx not_active IP Right Cessation
-
1999
- 1999-10-19 US US09/425,034 patent/US6433140B1/en not_active Expired - Fee Related
-
2000
- 2000-09-28 GR GR20000402074T patent/GR3034492T3/el not_active IP Right Cessation
-
2002
- 2002-07-03 NO NO20023224A patent/NO319156B1/no unknown
- 2002-07-16 US US10/196,460 patent/US6828418B2/en not_active Expired - Fee Related
-
2003
- 2003-08-26 FI FI20031199A patent/FI115633B/fi active IP Right Grant
- 2003-10-15 JP JP2003355706A patent/JP2004024276A/ja not_active Withdrawn
-
2004
- 2004-03-31 JP JP2004108131A patent/JP2004254697A/ja not_active Withdrawn
- 2004-11-03 US US10/980,722 patent/US20060009383A1/en not_active Abandoned
-
2005
- 2005-02-24 NO NO20050998A patent/NO20050998D0/no not_active Application Discontinuation
-
2006
- 2006-07-26 JP JP2006204005A patent/JP2006321813A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO953033L (no) | Stabile baktericid/permeabilitetsökende proteinprodukter og farmasöytiske preparater inneholdende disse | |
FI860153A (fi) | Oligopeptider, deras mellanprodukter och foerfarande foer deras framstaellning. | |
MXPA03002218A (es) | Peptidos antimicrobianos y metodos de uso. | |
PT711305E (pt) | Protegrinas | |
IL85020A0 (en) | Pancreatic secretory trypsin inhibitor and variants thereof,process expression vector and recombinant host therefor and pharmaceutical compositions containing it | |
ATE264913T1 (de) | Protease-resistente analoge des thrombomodulin | |
ES2114555T3 (es) | Nuevo interferon gamma humano recombinado. | |
ATE143974T1 (de) | Peptide des hiv-gag proteins, ihre herstellung und verwendung | |
Theofan et al. | Stable bactericidal/permeability-increasing protein muteins | |
DK547486A (da) | Peptider samt praeparater indeholdende disse | |
BR0107799A (pt) | Proteìna de interação de wt1 wtip |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |